6 days Ago By ABMN Staff
Alliancebernstein L.P. boosted its position in Veracyte, Inc.
( NASDAQ:VCYT – Free Report ) by 2.1% in the 4th quarter, HoldingsChannel reports. The firm owned 98,420 shares of the biotechnology company’s stock after purchasing an additional 2,000 shares during the period.
Alliancebernstein L.P.’s holdings in Veracyte were worth $3,897,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in VCYT. HighTower Advisors LLC acquired a new position in shares of Veracyte in the third quarter valued at approximately $554,000. State Street Corp grew its stake in Veracyte by 0.
3% in the 3rd quarter. State Street Corp now owns 2,916,515 shares of the biotechnology company’s stock worth $99,278,000 after acquiring an additional 7,920 shares during the period. Barclays PLC raised its holdings in Veracyte by 138.
6% in the 3rd quarter. Barclays PLC now owns 146,402 shares of the biotechnology company’s stock valued at $4,983,000 after acquiring an additional 85,033 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Veracyte by 1.
0% during the 3rd quarter. Geode Capital Management LLC now owns 1,844,713 shares of the biotechnology company’s stock worth $62,806,000 after purchasing an additional 17,921 shares during the period. Finally, Synovus Financial Corp boosted its holdings in shares of Veracyte by 16.
2% during the third quarter. Synovus Financial Corp now owns 22,865 shares of the biotechnology company’s stock worth $778,000 after purchasing an additional 3,195 shares during the last quarter. Veracyte Stock Up 1.
1 % VCYT opened at $32.14 on Tuesday. Veracyte, Inc.
has a 52-week low of $18.61 and a 52-week high of $47.32.
The company has a 50 day moving average of $34.00 and a two-hundred day moving average of $37.46.
The company has a market cap of $2.51 billion, a P/E ratio of -214.27 and a beta of 2.
03. Wall Street Analysts Forecast Growth Several equities analysts recently commented on VCYT shares. Stephens reiterated an “overweight” rating and issued a $45.
00 target price on shares of Veracyte in a research note on Wednesday, March 26th. Guggenheim cut their price objective on shares of Veracyte from $45.00 to $37.
00 and set a “buy” rating on the stock in a report on Wednesday, April 9th. Craig Hallum started coverage on shares of Veracyte in a report on Thursday, March 20th. They issued a “buy” rating and a $45.
00 target price for the company. UBS Group upped their price target on shares of Veracyte from $46.00 to $49.
00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $51.00 price target on shares of Veracyte in a report on Tuesday, February 25th.
One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.60.
View Our Latest Stock Report on Veracyte Veracyte Company Profile ( Free Report ) Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis.
The company was founded by Bonnie H. Featured Articles Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc.
( NASDAQ:VCYT – Free Report ). Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter .
.
